SUMMARY Endogenous vasopressin may interact with central autonomic nervous system factors in the regulation of cardiovascular function. In 25 morphine/chloralose-anesthetized dogs, we studied the magnitude of the pressor response produced by an infusion of angiotensin II (All) into the vertebral arteries (VA), before and after intracisternal (n = 10), intravertebral (n = 9), or intravenous (n = 6) administration of a competitive antagonist of arginine vasopressin (AVP) [d(CH 2 )5iyr(Me) AVP]. The dose response curve to vertebral artery infusion of AH (range 2-20 ng/ kg/mih) was significantly (p < 0.05) shifted to the right of control after injection of the AVP antagonist (10 Mg/kg) into the cisterna magna; the ED at 20 mm Hg being almost double after central AVP blockade. This effect of AVP blockade was confined only to the cardiovascular response mediated by All via the vertebral arteries. When pressor doses of All were injected into either a vein (i.v.) or the cisterna magna of these same dogs, the increases in mean blood pressure were the same before and after AVP antagonist treatment. In another group of anesthetized dogs, we investigated whether the reduced reactivity to intravertebral All could be duplicated by giving the AVP antagonist either via the vertebral artery or i.v. Only the cisterna magna route was effective in causing a blunting of the pressor response to vertebral artery AH. These data demonstrate a previously unknown interaction between vasopressin and the centrally mediated pressor response to intravertebral AH. T is well established that in the dog the area postrema of the fourth ventricle has a role in the neural control of cardiovascular function by acting, in part, to enhance central vasomotor sympathetic activity in response to increased blood levels of angiotensin II (All).
I
T is well established that in the dog the area postrema of the fourth ventricle has a role in the neural control of cardiovascular function by acting, in part, to enhance central vasomotor sympathetic activity in response to increased blood levels of angiotensin II (All). 1 " 5 In addition, recent data suggest that the effects of AH at the dog's area postrema may depend upon the activity of endogenous brain peptides such as the opioid system. 6 Other studies have indicated that there are reciprocal direct connections between the supraoptic (SON) and paraventricular nuclei (PVN) of the hypothalamus and the nucleus tractus solitarii (NTS) in the brain stem. 7 8 Long descending projections from PVN to the dorsal motor nuclei of the vagus nerve (DMV), the NTS and upper spinal cord have 9 These observations, in conjunction with the recent reports that hypertension is associated with alterations in vasopressin levels in the brain stem of spontaneously hypertensive rats (SHRs), 10 make this peptide another possible candidate to interact with AH in determining the degree of sympathetic activation at the brain stem. To investigate one facet of the function of brain vasopressin upon the reflex regulation of arterial pressure, we determined whether blockade of the activity of this neuropeptide system alters the ability of AH to exert an increase in sympathetic activity via the area postrema pressor pathway.
Methods
Experiments were performed in 25 male mongrel dogs (body weight = 21.6 ± 0.4 kg) anesthetized with alpha-chloralose (65 mg/kg, i.v.) after premedication with morphine (2 mg/kg, i.m.) and respirated mechanically. Supplemental doses of these anesthetic agents were given as necessary. Both vertebral arteries were isolated and cannulated using fine 20 g catheters (Angiocath, Deseret Company, Sandy, Utah) so as not to interrupt blood flow. 6 Additional catheters were VASOPRESSIN AND ANGIOTENSIN WMichelini et al.
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placed in a femoral artery and vein for blood pressure measurements and drug administration, respectively. After placing the dog's head in a stereotaxic head holder, the foramen magnum was exposed via a midline incision from the crest of the occiput to the Cl region, and a 20 g cannula was affixed to administer drugs directly into the cerebrospinal fluid (CSF) of the cisterna magna. Blood pressure and heart rate (HR) were recorded before and during infusion of All (Asp'-Ile 3 All, synthesized by Dr. M. Khosla) either via the vertebral arteries (dose range = 2.0 to 20 ng/kg/min), intravenously (i.v.), or directly into the cisterna magna. The order of AN administration was randomized, and the various amounts of the peptide were given both before and after pretreatment with a specific vasopressin (AVP) antagonist" [d(CH 2 ) 5 Tyr (Me) AVP, Bachem Inc, Torrance, California] given via the cisterna magna of 10 dogs (10 /xg/kg), infused into the vertebral arteries of nine others (3.4 /i,g/kg/min for 3 minutes), or given i.v. (10 /xg/kg) in a remaining six animals. Normal saline (0.9% sodium chloride) was used as vehicle. In each experiment, blockade of the pressor activity of vasopressin by the AVP antagonist was confirmed by the absence of a rise in blood pressure following infusion of arginine 8 -vasopressin (Vega Biochemicals, Tucson, Arizona) by the corresponding route of administration. In the experiments in which the AVP antagonist was given via the cisterna magna, the potency of the blockade was determined by giving AVP at a dose of 60 ng/kg. Then the AVP antagonist was given via the vertebral arteries or into a vein, the test doses of AVP were 20 ng/kg/min. We have shown recently 12 that these doses of AVP cause prominent hypertensive responses (15-20 mm Hg) associated with bradycardia and that the AVP antagonist in the doses used in these experiments effectively blocked the pressor effects of AVP for at least 2 hours.
At the completion of each experiment, Evans blue dye (0.9 mg in 0.2 ml of saline; Harvey Labs, Inc., Philadelphia, Pennsylvania) was injected into the cisterna magna, and the distribution of the dye was examined in the brain to determine what structures might be reached by drugs given via this route.
The means and standard errors of the peak of the pressor and HR responses were calculated for each dose and condition for all dogs. These data were compared using either the Student's t test for paired and unpaired data," or analysis of variance and covariance for repeated measurements.
14 Differences were considered significant forp < 0.05.
Results
In 10 dogs anesthetized with a mixture of morphine and chloralose, baseline mean arterial pressure (MAP) and HR averaged 105 ± 5 mm Hg and 43 ± 3 bpm respectively. A 3-minute infusion of All into the vertebral arteries at doses between 2 and 20 ng/kg/min caused reproducible increases in MAP and a shortlasting rise in HR. For the group as a whole, the peak increases in MAP above baseline values averaged 13 ± 2 mm Hg at a 2 ng/kg/min dose of All, 17 ± 2 mm Hg at a dose of 5 ng/kg/min, and 32 ± 3 mm Hg at 20 ng/kg/min ( fig. 1 ). The magnitude of the change in MAP produced by the infusion of All via the vertebral arteries was statistically significant for each dose tested (p < 0.001) and comparable to those reported previously. 16 As expected, the two smaller doses of infused All (2 and 5 ng/kg/min) produced minor, if any, increases in MAP when given into a vein. At the highest dose tested (20 ng/kg/min), intravertebral All caused a greater increase in MAP than by the i.v. route (vertebral artery 32 ± 3 vs 26 ± 2 mm Hg by the i.v. route) but the difference was not statistically significant (p > 0.05).
The injection of a competitive antagonist of the vascular actions of arginine vasopressin" into the CSF contained in the cisterna magna of these 10 dogs caused a slight increase in baseline MAP (group average = 117 ± 5 mm Hg; mean difference = + 12 ± 3 mm Hg, p < 0.01) and HR (49 ± 3 bpm; mean difference + 6 ± 2 bpm,p < 0.05). Following delivery of the AVP antagonist via the cisterna magna route, the peak of the pressor response to the various doses of intravertebral All became smaller in magnitude, producing a statistically significant (p < 0.05) downward shift of the dose response curve ( fig. 1 ). From the data shown in figure 1 , we calculated that the dose of All needed to raise arterial pressure by 20 mm Hg after cisterna magna administration of the AVP antagonist was almost doubled. In addition, linear regression analysis revealed a 29.5% decrease in the slope of the dose response curve and a 17% decrease in the value of the intercept (see legend of fig. 1 ). Figure 2 shows that the AVP antagonist given via the cisterna magna route affected both the rise time as well as the plateau of the pressor response. At the largest dose, the threshold and half-maximal values before and after cisterna magna injection of the AVP antagonist were changed as follows: before giving the AVP blocker, the onset of the pressor response occurred 5 to 10 seconds after the start of the infusion, while the half-maximal response ( + 18% above control values) was reached in approximately 50 seconds and coincided with the peak of the short-lasting increases in HR ( + 1 1 % above baseline values). After AVP blockade, the half-maximal response ( + 1 1 % above baseline values) was attained after 70 seconds, and the smaller peak change in heart rate ( + 5%) was similarly delayed ( fig. 2 ). Figure 3 shows that the central action of the AVP antagonist was confined to the elevations in blood pressure produced by AH given via the vertebral arteries. When comparable rises in pressure were attained by giving All into a vein, the pressor response was the same before and after cistema magna injection of the AVP blocker. The same negative result was obtained when we compared the increases in pressure resulting from injection of All directly into the cistema magna ( fig. 3 ). With this mode of administration, blood pressure rose 12 ± 2 mm Hg before and 12 ± 4 mm Hg after pretreatment with the AVP antagonist (p > 0.05, fig. 3 ).
To ascertain whether the AVP antagonist acted either centrally or peripherally to reduce the pressor potency of intravertebrally infused All, we examined in 15 other anesthetized dogs the effect of giving the AVP antagonist via either the vertebral arteries or intravenously. The findings are summarized in tables 1 and 2. Effectiveness of the blockade was assessed by demonstrating a sustained disappearance of a pressor response to the infusion of AVP by either the vertebral artery or i.v. routes (see Methods). As summarized in tables 1 and 2, in the nine dogs in which the AVP antagonist was infused via the vertebral arteries, shortterm infusions of All via the same route produced increases in pressure and HR that were of the same magnitude before and after treatment with the AVP blocker. The same results were obtained in six other dogs in which the AVP blocker was given i.v. (tables 1 and 2). 
FIGURE 4. A schematic outline of the surface of the dog brain (dorsal and ventral views) is used to denote the regions of Evans blue deposition 15 minutes after injection of the dye into the cisterna magna.
At the completion of each experiment, 0.2 ml of Evans blue dye was injected into the cisterna magna. Macroscopic examination of the distribution of the dye around the surface of the entire brain and upper spinal cord (C2) showed a preferential staining of the surface of the ventral brain stem, particularly at the region of the preoptic recess and the mammillary bodies ( fig. 4) . Both the dorsal and ventral surface of the upper spinal cord were dyed, but the lateral, third, and fourth cerebral ventricles were not. The area postrema was also free of any dye.
Discussion
Recent data indicate that brain peptidergic pathways participate in the regulation of cardiovascular function, and may also contribute directly to the dysregulation of blood pressure in several forms of hypertension. 1015 To obtain a further insight into the basic mechanisms by which neuropeptides act to regulate arterial pressure, we produced short-term increases in vasomotor sympathetic drive with intravertebral All and then measured the magnitude of the blood pressure and HR responses both before and after administration of a competitive blocker of the pressor actions of arginine vasopressin. Numerous studies have shown that the infusion of All into the vascular territory of the dog's vertebral arteries causes a prompt increase in sympathetic nerve activity due to an action of the peptide upon neuroreceptors located in the area postrema. '• 4 -l6 In the present experiments, the magnitude and characteristics of the pressor response to intravertebral All were like those reported previously;'-6 in addition, we made certain that the amounts of the specific inhibitor of AVP given in these experiments were sufficient to block the vasoconstrictor response due to the injection of large doses of AVP by each route of administration.
Our results indicate that in anesthetized dogs the delivery of the AVP inhibitor into the CSF of the cisterna magna caused a moderate but consistent decrease in both the magnitude and the rapidity of the pressor response elicited by vertebral artery AH. The reduced height of the pressor response was associated with a diminution of the characteristically small and short lasting increases in HR that are a part of the cardiovascular pattern elicited by the action of All upon the area postrema. 1 ' l3 It could be assumed that the moderate blunting of the pressor responses to vertebral artery All was due to an elevation in baseline MAP following injection of the AVP antagonist into the cisterna magna. However, this factor cannot account for the observed changes since a similar rise in control MAP occurred when the AVP antagonist was delivered via the vertebral arteries or into a vein, yet the pressor responses to the administration of All either into the vertebral arteries or i.v. remained unaffected (table 1) . Although we do not have an explanation for the effects of the AVP antagonist qpon baseline arterial pressure, it is unlikely that the rises in pressure reflect that these compounds possess partial agonistic properties."' l5
These newly described effects of a centrally administered AVP antagonist were observed for each of the three doses of intravertebral All used in the experiments. On the other hand, when All was given directly into a vein in either the same or larger doses, the magnitude of the pressor response was not modified by VASOPRESSIN AND ANGIOTENSIN WMichelini et al.
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pretreatment with the AVP antagonist. Because i.v. AH causes direct vasoconstriction and a baroreceptormediated reflex withdrawal of sympathetic nerve activity 17 while, conversely, vertebral artery All produces a neurogenically mediated increase in vascular resistance, 3 ' 18 it is possible to suggest thaj the action of the AVP antagonist was linked to the mechanism that results in the activation of sympathetic nerve activity by All. 16 Since the modulatory effect of the AVP inhibitor upon the magnitude of the intravertebrally elicited pressor response to All could not be duplicated by giving this compound either via the vertebral artery route or into a vein, it does not appear likely that this action is exercised by the blockade of a vasopressinergic site that is either located in the periphery or is reached through a gap in the blood brain barrier of the vertebral artery territory. Since Kruszynski et al." have shown that these potent inhibitors of vasopressin have some antagonist properties against oxytocin, the present findings do not rule out that the effects of d(CH 2 ) 5 Tyr(Me) AVP are in part related to central blockade of the latter peptide.
A variety of studies have shown that vasopressin interacts with the baroreceptor reflex, 19 -21 and that it has a central stimulating action on the cardioinhibitory neurons in the region of the vagaJ nuclei. 22 Other investigators have shown that one aspect of the central action of vasopressin may involve neural projections to the NTS from vasopressin-neurophysin cells located in the PVN, SON, and suprachiasmatic nuclei. 152324 In the present experiments, it would appear that the modulatory influence of a central vasopressinergic pathway upon the pressor response induced by VA All may not occur at either the area postrema or other brain stem sites perfused by the vertebral arteries. The preferential distribution of Evans' blue to the ventral aspects of the brain suggests, but obviously does not prove, that the effect of the AVP antagonist may have taken place at a region rostral to the lower brain stem. In. support of this hypothesis we have shown that the reaction product of horseradish peroxidase (HRP) delivered into the cisterna magna is preferentially localized in the ependymal layer and perivascular spaces of the ventral brain stem as far rostral as the preoptic region. 23 In addition, the HRP product did not stain the area postrema and medial portion of the NTS, 25 an indication that large molecules do not penetrate at these sites via the cerebrospinal route.
The observation that CSF administration of the AVP antagonist reduces the activation in sympathetic nerve activity that results from the action of All upon the area postrema may be taken as evidence for an endogenous role of vasopressin in modulating the effect of All upon central autonomic function. It has been shown before 26 that administration of AVP into a lateral ventricle of anesthetized cats produced a prompt fall in blood pressure; moreover, Ciriello and Calaresu 27 have reported that the bradycardia due to carotid sinus stimulation can be attenuated in cats by concomitant stimulation of the PVN or SON. Since neurons in these nuclei synthesize AVP 28 " 30 and projections 89 from these cells may exert an inhibitory influence on the baroreceptor reflex, 15 -24 it is conceivable that the AVP antagonist acted within this pathway to prevent the central inhibition of the baroreceptor reflex. Under these circumstances, the rises in pressure produced by VA All will be blunted because the baroreceptor mechanism will be more likely to prevent the sympatho-excitation produced by All at the level of the area postrema. This interpretation is consonant with previous experiments indicating that a part of the centrally mediated rise in blood pressure by All may be due to central inhibition of the baroreceptor reflex. 3 Although this interpretation forms the basis for an attractive hypothesis, the findings of the present experiments could be explained by other mechanisms as well. 2021 Because the modulating action of AVP, or alternatively oxytocin, upon the central mechanism regulating cardiovascular function appears to be quite complex in nature, 1924 further work is needed before definitive conclusions can be drawn.
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